<DOC>
	<DOCNO>NCT00276016</DOCNO>
	<brief_summary>This Phase 3 , single-dose , investigator-blind , randomize , placebo-controlled , crossover study , conduct single site Austria , outside normal grass pollen season . An allergic reaction induce expose subject grass pollen Vienna Challenge Chamber ( VCC ) . Subjects receive single dose follow treatment accord randomization sequence : Phenylephrine 12 mg immediate-release capsule , pseudoephedrine 60 mg immediate-release tablet , placebo capsule . There minimum 5-day washout period treatment . Subjects complete symptom evaluation throughout study . The nasal decongestant effect phenylephrine compare placebo use subjective symptom evaluation . The safety profile ( adverse event vital sign ) treatment also evaluate .</brief_summary>
	<brief_title>The Effects Phenylephrine Compared With Those Placebo Pseudoephedrine Nasal Congestion Subjects With Seasonal Allergic Rhinitis ( SAR ) ( P04579 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<criteria>Skin test positive grass pollen allergen use chamber Screening within prior 12 month . A negative urine pregnancy test Screening monthly interval female subject childbearing potential . The following minimum score evaluation time point 120minute screening period challenge session : 1 . Nasal Congestion Score least 2 ( moderate ) ; 2 . Total Nasal Symptoms Score least 6 ; 3 . Total Nonnasal Symptoms Score least 2 . Freedom clinically significant disease , SAR , would interfere study evaluation . Exclusion Criteria : An upper low respiratory tract infection within 4 week Screening . Dependence upon nasal , oral , ocular decongestant , nasal topical antihistamine , nasal steroid , opinion investigator . A known potential hypersensitivity , allergy , idiosyncratic reaction study drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>